RenovoRx (NASDAQ:RNXT – Get Rating) and Inozyme Pharma (NASDAQ:INZY – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for RenovoRx and Inozyme Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RenovoRx | 0 | 0 | 0 | 0 | N/A |
| Inozyme Pharma | 0 | 0 | 4 | 0 | 3.00 |
Inozyme Pharma has a consensus target price of $16.00, suggesting a potential upside of 171.65%. Given Inozyme Pharma’s higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than RenovoRx.
Volatility & Risk
Institutional & Insider Ownership
13.6% of RenovoRx shares are held by institutional investors. Comparatively, 76.4% of Inozyme Pharma shares are held by institutional investors. 9.0% of RenovoRx shares are held by insiders. Comparatively, 9.7% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares RenovoRx and Inozyme Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RenovoRx | N/A | -107.13% | -94.97% |
| Inozyme Pharma | N/A | -54.02% | -47.55% |
Valuation & Earnings
This table compares RenovoRx and Inozyme Pharma’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RenovoRx | N/A | N/A | -$9.89 million | ($1.09) | -2.61 |
| Inozyme Pharma | N/A | N/A | -$67.06 million | ($1.89) | -3.12 |
Inozyme Pharma is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.
Summary
Inozyme Pharma beats RenovoRx on 7 of the 10 factors compared between the two stocks.
About RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
About Inozyme Pharma
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
